The structure and functions of P-glycoprotein

Current Medicinal Chemistry

Volumn 17, Issue 8, 2010, Pages 786-800

  Li, Y ^a   Yuan, H ^a   Yang, K ^a   Xu, W ^a   Tang, W ^b   Li, X ^a  

^a SHANDONG UNIVERSITY   (China)

^b UNIVERSITY OF TOKYO   (Japan)

Author keywords

Chemosensitizers; Function; MDR; P glycoprotein (P gp); Structure

Indexed keywords

4 [5 (4 METHYL 1 PIPERAZINYL)[2,5' BI 1H BENZIMIDAZOL] 2' YL]PHENOL; ABC TRANSPORTER; ANTHRACENE DERIVATIVE; ANTHRACYCLINE DERIVATIVE; BISANTRENE; CAMPTOTHECIN DERIVATIVE; COLCHICINE; CRT 11; DAUNORUBICIN; DOXORUBICIN; EPIPODOPHYLLOTOXIN DERIVATIVE; EPIRUBICIN; ETOPOSIDE; GLYCOPROTEIN P; HOE 33342; IDARUBICIN; MITOXANTRONE; NAVELBINE; NUCLEOTIDE BINDING OLIGOMERIZATION DOMAIN PROTEIN; NUCLEOTIDE BINDING PROTEIN; PACLITAXEL; POLYPEPTIDE ANTIBIOTIC AGENT; PROTEINASE INHIBITOR; TAXANE DERIVATIVE; TENIPOSIDE; TOPOTECAN; UNCLASSIFIED DRUG; UNINDEXED DRUG; VINBLASTINE; VINCA ALKALOID; VINCRISTINE; VINDESINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ALZHEIMER DISEASE; BIOAVAILABILITY; CANCER RESISTANCE; CONFORMATIONAL TRANSITION; CYSTIC FIBROSIS; DNA POLYMORPHISM; DRUG BINDING; DRUG DESIGN; DRUG PROTEIN BINDING; GENE OVEREXPRESSION; GLYCOSYLATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYDROLYSIS; HYDROPHOBICITY; INTESTINE ABSORPTION; MEMBRANE TRANSPORT; MICROTUBULE ASSEMBLY; MULTIDRUG RESISTANCE; PARASITISM; PROTEIN DOMAIN; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; PROTEIN STRUCTURE; REVIEW; SEQUENCE HOMOLOGY; UPREGULATION;

BIOLOGICAL TRANSPORT; DRUG DESIGN; DRUG RESISTANCE, MULTIPLE; HUMANS; MODELS, MOLECULAR; NEURODEGENERATIVE DISEASES; P-GLYCOPROTEIN; POLYMORPHISM, GENETIC; SUBSTRATE SPECIFICITY;

EID: 77950672853     PISSN: 09298673     EISSN: None     Source Type: Journal    
DOI: 10.2174/092986710790514507     Document Type: Review

References (127)

1. 2 terminus of P-glycoprotein. Clin. Cancer Res., 2005, 11, 5833-5839
2. Ho, E.A.; Piquette-Miller, M. Regulation of multidrug resistance by pro-inflammatory cytokines. Curr. Cancer Drug Targets, 2006, 6, 295-311. (Pubitemid 43961865)
3. Coburger, C.; Wollmann, J.; Baumert, C.; Krug, M.; Molnar, J.; Lage, H.; Hilgeroth, A. Novel insight in structure-activity relationship and bioanalysis of P-glycoprotein targeting highly potent tetrakishydroxymethyl substituted 3,9-diazatetraasteranes. J. Med. Chem., 2008, 51, 5871-5874
4. Colabufo, N.A.; Berardi, F.; Cantore, M.; Perrone, M.G.; Contino, M.; Inglese, C.; Niso, M.; Perrone, R.; Azzariti, A.; Simone, G.M.; Paradiso, A. 4-Biphenyl and 2-naphthyl substituted 6,7-dimethoxytetrahydroisoquinoline derivatives as potent P-gp modulators. Bioorg. Med. Chem., 2008, 16, 3732-3743 (Pubitemid 351484037)
5. Bodor, M.; Kelly, E.J.; Ho, R.J. Characterization of the human MDR1 gene. AAPS J., 2005, 7, E1-5.
6. Loo, T.W.; Bartlett, M.C.; Clarke, D.M. The dileucine motif at the COOH terminus of human multidrug resistance P-glycoprotein is important for folding but not activity. J. Biol. Chem., 2005, 280, 2522-2528
7. Gottesman, M.M. Multidrug resistance during chemical carcinogenesis: a mechanism revealed? J. Natl. Cancer Inst., 1988, 80, 1352-1353
8. Ambudkar, S.V.; Dey, S.; Hrycyna, C.A.; Ramachandra, M.; Pastan, I.; Gottesman, M.M. Biochemical, cellular, and pharmacological aspects of the multidrug transporter. Annu. Rev. Pharmacol. Toxicol., 1999, 39, 361-398
9. Gribar, J.J.; Ramachandra, M.; Hrycyna, C.A.; Dey, S.; Ambudkar, S.V. Functional characterization of glycosylation-deficient human P-glycoprotein using a vaccinia virus expression system. J. Membr. Biol., 2000, 173, 203-214
10. Tang, Y.; Beuerlein, G.; Pecht, G.; Chilton, T.; Huse, W.D.; Watkins, J.D. Use of a peptide mimotope to guide the humanization of MRK-16, an anti-P-glycoprotein monoclonal antibody. J. Biol. Chem., 1999, 274, 27371-27378 (Pubitemid 129527777)
11. Germann, U.A. P-glycoprotein - a mediator of multidrug resistance in tumour cells. Eur. J. Cancer, 1996, 32A, 927-944 (Pubitemid 26191761)
12. Loo, T.W.; Clarke, D.M. Do drug substrates enter the common drug-binding pocket of P-glycoprotein through "gates"? Biochem. Biophys. Res. Commun., 2005, 329, 419-422
13. Loo, T.W.; Clarke, D.M. Merck Frosst Award Lecture 1998. Molecular dissection of the human multidrug resistance Pglycoprotein. Biochem. Cell Biol., 1999, 77, 11-23.
14. Rothnie, A.; Storm, J.; McMahon, R.; Taylor, A.; Kerr, I.D.; Callaghan, R. The coupling mechanism of P-glycoprotein involves residue L339 in the sixth membrane spanning segment. FEBS Lett., 2005, 579, 3984-3990 (Pubitemid 40961900)
15. Loo, T.W.; Clarke, D.M. The transmembrane domains of the human multidrug resistance P-glycoprotein are sufficient to mediate drug binding and trafficking to the cell surface. J. Biol. Chem., 1999, 274, 24759-24765 (Pubitemid 129529362)
16. Loo, T.W.; Clarke, D.M. Superfolding of the partially unfolded core-glycosylated intermediate of human P-glycoprotein into the mature enzyme is promoted by substrate-induced transmembrane domain interactions. J. Biol. Chem., 1998, 273, 14671-14674
17. Pleban, K.; Kaiser, D.; Kopp, S.; Peer, M.; Chiba, P.; Ecker, G.F. Targeting drug-efflux pumps -- a pharmacoinformatic approach. Acta Biochim. Pol., 2005, 52, 737-740
18. Loo, T.W.; Bartlett, M.C.; Clarke, D.M. Processing mutations located throughout the human multidrug resistance P-glycoprotein disrupt interactions between the nucleotide binding domains. J. Biol. Chem., 2004, 279, 38395-38401
19. Wan, C.K.; Zhu, G.Y.; Shen, X.L.; Chattopadhyay, A.; Dey, S.; Fong, W.F. Gomisin A alters substrate interaction and reverses Pglycoprotein-mediated multidrug resistance in HepG2-DR cells. Biochem. Pharmacol., 2006, 72, 824-837
20. Cianchetta, G.; Singleton, R.W.; Zhang, M.; Wildgoose, M.; Giesing, D.; Fravolini, A.; Cruciani, G.; Vaz, R.J. A pharmacophore hypothesis for P-glycoprotein substrate recognition using GRIND-based 3D-QSAR. J. Med. Chem., 2005, 48, 2927-2935
21. Frelet, A.; Klein, M. Insight in eukaryotic ABC transporter function by mutation analysis. FEBS Lett., 2006, 580, 1064-1084 (Pubitemid 43185287)
22. Loo, T.W.; Bartlett, M.C.; Clarke, D.M. The "LSGGQ" motif in each nucleotide-binding domain of human P-glycoprotein is adjacent to the opposing walker A sequence. J. Biol. Chem., 2002, 277, 41303-41306
23. Kim, I.W.; Peng, X.H.; Sauna, Z.E.; FitzGerald, P.C.; Xia, D.; Muller, M.; Nandigama, K.; Ambudkar, S.V. The conserved tyrosine residues 401 and 1044 in ATP sites of human P-glycoprotein are critical for ATP binding and hydrolysis: evidence for a conserved subdomain, the A-loop in the ATP-binding cassette. Biochemistry, 2006, 45, 7605-7616
24. Vigano, C.; Julien, M.; Carrier, I.; Gros, P.; Ruysschaert, J.M. Structural and functional asymmetry of the nucleotide-binding domains of P-glycoprotein investigated by attenuated total reflection Fourier transform infrared spectroscopy. J. Biol. Chem., 2002, 277, 5008-5016 (Pubitemid 34968540)
25. Gottesman, M.M.; Pastan, I.; Ambudkar, S.V. P-glycoprotein and multidrug resistance. Curr. Opin. Genet. Dev., 1996, 6, 610-617
26. Eytan, G.D.; Regev, R.; Assaraf, Y.G. Functional reconstitution of P-glycoprotein reveals an apparent near stoichiometric drug transport to ATP hydrolysis. J. Biol. Chem., 1996, 271, 3172-3178
27. Loo, T.W.; Clarke, D.M. Cross-linking of human multidrug resistance P-glycoprotein by the substrate, tris-(2-maleimidoethyl) amine, is altered by ATP hydrolysis. Evidence for rotation of a transmembrane helix. J. Biol. Chem., 2001, 276, 31800-31805 (Pubitemid 37384829)
28. Druley, T.E.; Stein, W.D.; Roninson, I.B. P-glycoprotein-mediated colchicine resistance in different cell lines correlates with the effects of colchicine on P-glycoprotein conformation. Biochemistry, 2001, 40, 4312-4322
29. Aanismaa, P.; Gatlik-Landwojtowicz, E.; Seelig, A. P-glycoprotein senses its substrates and the lateral membrane packing density: consequences for the catalytic cycle. Biochemistry, 2008, 47, 10197-10207
30. Ferté, J. Analysis of the tangled relationships between P-glycoprotein-mediated multidrug resistance and the lipid phase of the cell membrane. Eur. J. Biochem., 2000, 267, 277-294 (Pubitemid 30072888)
31. Hrycyna, C.A.; Airan, L.E.; Germann, U.A.; Ambudkar, S.V.; Pastan, I.; Gottesman, M.M. Structural flexibility of the linker region of human P-glycoprotein permits ATP hydrolysis and drug transport. Biochemistry, 1998, 37, 13660-13673
32. Loo, T.W.; Bartlett, M.C.; Clarke, D.M. ATP hydrolysis promotes interactions between the extracellular ends of transmembrane segments 1 and 11 of human multidrug resistance P-glycoprotein. Biochemistry, 2005, 44, 10250-10258
33. Loo, T.W.; Clarke, D.M. Determining the dimensions of the drug-binding domain of human P-glycoprotein using thiol cross-linking compounds as molecular rulers. J. Biol. Chem., 2001, 276, 36877-36880 (Pubitemid 37384096)
34. Loo, T.W.; Bartlett, M.C.; Clarke, D.M. Val133 and Cys137 in transmembrane segment 2 are close to Arg935 and Gly939 in transmembrane segment 11 of human P-glycoprotein. J. Biol. Chem., 2004, 279, 18232-18238
35. Loo, T.W.; Bartlettt, M.C.; Clarke, D.M. Transmembrane segment 1 of human P-glycoprotein contributes to the drug-binding pocket. Biochem. J., 2006, 396, 537-545 (Pubitemid 44228168)
36. Loo, T.W.; Clarke, D.M. Defining the drug-binding site in the human multidrug resistance P-glycoprotein using a methanethiosulfonate analog of verapamil, MTS-verapamil. J. Biol. Chem., 2001, 276, 14972-14979 (Pubitemid 37373379)
37. Loo, T.W.; Bartlett, M.C.; Clarke, D.M. Transmembrane segment 7 of human P-glycoprotein forms part of the drug-binding pocket. Biochem. J., 2006, 399, 351-359 (Pubitemid 44570297)
38. Loo, T.W.; Bartlett, M.C.; Clarke, D.M. Simultaneous binding of two different drugs in the binding pocket of the human multidrug resistance P-glycoprotein. J. Biol. Chem., 2003, 278, 39706-39710
39. Loo, T.W.; Bartlett, M.C.; Clarke, D.M. Substrate-induced conformational changes in the transmembrane segments of human Pglycoprotein. Direct evidence for the substrate-induced fit mechanism for drug binding. J. Biol. Chem., 2003, 278, 13603-13606
40. Loo, T.W.; Clarke, D.M. Location of the rhodamine-binding site in the human multidrug resistance P-glycoprotein. J. Biol. Chem., 2002, 277, 44332-44338 (Pubitemid 36157868)
41. Lugo, M.R.; Sharom, F.J. Interaction of LDS-751 with Pglycoprotein and mapping of the location of the R drug binding site. Biochemistry, 2005, 44, 643-655
42. Loo, T.W.; Bartlett, M.C.; Clarke, D.M. Disulfide cross-linking analysis shows that transmembrane segments 5 and 8 of human P glycoprotein are close together on the cytoplasmic side of the membrane. J. Biol. Chem., 2004, 279, 7692-7697
43. Seigneuret, M.; Garnier-Suillerot, A. A structural model for the open conformation of the mdr1 P-glycoprotein based on the MsbA crystal structure. J. Biol. Chem., 2003, 278, 30115-30124 (Pubitemid 36962404)
44. Stenham, D.R.; Campbell, J.D.; Sansom, M.S.; Higgins, C.F.; Kerr, I.D.; Linton, K.J. An atomic detail model for the human ATP binding cassette transporter P-glycoprotein derived from disulfide cross-linking and homology modeling. FASEB J., 2003, 17, 2287-2289
45. Pajeva, I.K.; Globisch, C.; Wiese, M. Structure-function relationships of multidrug resistance P-glycoprotein. J. Med. Chem., 2004, 47, 2523-2533 (Pubitemid 38580090)
46. Rosenberg, M.F.; Callaghan, R.; Ford, R.C.; Higgins, C.F. Structure of the multidrug resistance P-glycoprotein to 2.5 nm resolution determined by electron microscopy and image analysis. J. Biol. Chem., 1997, 272, 10685-10694 (Pubitemid 27181079)
47. Rosenberg, M.F.; Kamis, A.B.; Callaghan, R.; Higgins, C.F.; Ford, R.C. Three-dimensional structures of the mammalian multidrug resistance P-glycoprotein demonstrate major conformational changes in the transmembrane domains upon nucleotide binding. J. Biol. Chem., 2003, 278, 8294-8299
48. Pajeva, I.K.; Wiese, M. Pharmacophore model of drugs involved in P-glycoprotein multidrug resistance: explanation of structural variety (hypothesis). J. Med. Chem., 2002, 45, 5671-5686 (Pubitemid 35453760)
49. Vandevuer, S.; Van Bambeke, F.; Tulkens, P.M.; Prévost, M. Predicting the three-dimensional structure of human P-glycoprotein in absence of ATP by computational techniques embodying crosslinking data: insight into the mechanism of ligand migration and binding sites. Proteins, 2006, 63, 466-478
50. Al-Shawi, M.K.; Omote, H. The remarkable transport mechanism of P-glycoprotein: a multidrug transporter. J. Bioenerg. Biomembr., 2005, 37, 489-496 (Pubitemid 43725181)
51. Murakami, S.; Nakashima, R.; Yamashita, E.; Matsumoto, T.; Yamaguchi, A. Crystal structures of a multidrug transporter reveal a functionally rotating mechanism. Nature, 2006, 443, 173-179
52. Varma, M.V.; Ashokraj, Y.; Dey, C.S.; Panchagnula, R. Pglycoprotein inhibitors and their screening: a perspective from bioavailability enhancement. Pharmacol. Res., 2003, 48, 347-359 (Pubitemid 36945333)
53. Ito, S.; Woodland, C.; Sarkadi, B.; Hockmann, G.; Walker, S.E.; Koren, G. Modeling of P-glycoprotein-involved epithelial drug transport in MDCK cells. Am. J. Physiol., 1999, 46, F84-96.
54. Tran, T.T.; Mittal, A.; Aldinger, T.; Polli, J.W.; Ayrton, A.; Ellens, H.; Bentz, J. The elementary mass action rate constants of P-gp transport for a confluent monolayer of MDCKII-hMDR1 cells. Biophys. J., 2005, 88, 715-738 (Pubitemid 40070714)
55. Bentz, J.; Tran, T.T.; Polli, J.W.; Ayrton, A.; Ellens, H. The steady-state Michaelis-Menten analysis of P-glycoprotein mediated transport through a confluent cell monolayer cannot predict the correct Michaelis constant Km. Pharm. Res., 2005, 22, 1667-1677 (Pubitemid 41355906)
56. Ashida, H.; Oonishi, T.; Uyesaka, N. Kinetic analysis of the mechanism of action of the multidrug transporter. J. Theor. Biol., 1998, 195, 219-232 (Pubitemid 28528827)
57. Homolya, L.; Hollo, Z.; Germann, U.A.; Pastan, I.; Gottesman, M.M.; Sarkadi, B. Fluorescent cellular indicators are extruded by the multidrug resistance protein. J. Biol. Chem., 1993, 268, 21493-21496 (Pubitemid 23320634)
58. Raviv, Y.; Pollard, H.B.; Bruggemann, E.P.; Pastan, I.; Gottesman, M.M. Photosensitized labeling of a functional multidrug transporter in living drug-resistant tumor cells. J. Biol. Chem., 1990, 265, 3975-3980 (Pubitemid 20096035)
59. Loo, T.W.; Bartlett, M.C.; Clarke, D.M. Drug binding in human Pglycoprotein causes conformational changes in both nucleotidebinding domains. J. Biol. Chem., 2003, 278, 1575-1578
60. Loo, T.W.; Clarke, D.M. Identification of residues in the drug-binding domain of human P-glycoprotein. Analysis of transmembrane segment 11 by cysteine-scanning mutagenesis and inhibition by dibromobimane. J. Biol. Chem., 1999, 274, 35388-35392
61. Tombline, G.; Bartholomew, L.; Gimi, K.; Tyndall, G.A.; Senior, A.E. Synergy between conserved ABC signature Ser residues in Pglycoprotein catalysis. J. Biol. Chem., 2004, 279, 5363-5373
62. Sauna, Z.E.; Muller, M.; Peng, X.H.; Ambudkar, S.V. Importance of the conserved Walker B glutamate residues, 556 and 1201, for the completion of the catalytic cycle of ATP hydrolysis by human P-glycoprotein (ABCB1). Biochemistry, 2002, 41, 13989-14000
63. Loo, T.W.; Bartlett, M.C.; Clarke, D.M. Permanent activation of the human P-glycoprotein by covalent modification of a residue in the drug-binding site. J. Biol. Chem., 2003, 278, 20449-20452
64. Loo, T.W.; Bartlett, M.C.; Clarke, D.M. Methanethiosulfonate derivatives of rhodamine and verapamil activate human Pglycoprotein at different sites. J. Biol. Chem., 2003, 278, 50136-50141
65. Rosenberg, M.F.; Callaghan, R.; Modok, S.; Higgins, C.F.; Ford, R.C. Three-dimensional structure of P-glycoprotein: the transmembrane regions adopt an asymmetric configuration in the nucleotidebound state. J. Biol. Chem., 2005, 280, 2857-2862
66. Loo, T.W.; Clarke, D.M. Vanadate trapping of nucleotide at the ATP-binding sites of human multidrug resistance P-glycoprotein exposes different residues to the drug-binding site. Proc. Natl. Acad. Sci. U S A, 2002, 99, 3511-3516
67. Sauna, Z.E.; Ambudkar, S.V. Characterization of the catalytic cycle of ATP hydrolysis by human P-glycoprotein. The two ATP hydrolysis events in a single catalytic cycle are kinetically similar but affect different functional outcomes. J. Biol. Chem., 2001, 276, 11653-11661 (Pubitemid 37385318)
68. Loo, T.W.; Clarke, D.M. Recent progress in understanding the mechanism of P-glycoprotein-mediated drug efflux. J. Membr. Biol., 2005, 206, 173-185
69. Sauna, Z.E.; Nandigama, K.; Ambudkar, S.V. Exploiting reaction intermediates of the ATPase reaction to elucidate the mechanism of transport by P-glycoprotein (ABCB1). J. Biol. Chem., 2006, 281, 26501-26511
70. Rosenberg, M.F.; Velarde, G.; Ford, R.C.; Martin, C.; Berridge, G.; Kerr, I.D.; Callaghan, R.; Schmidlin, A.; Wooding, C.; Linton, K.J.; Higgins, C.F. Repacking of the transmembrane domains of Pglycoprotein during the transport ATPase cycle. EMBO J., 2001, 20, 5615-5625
71. Loo, T.W.; Bartlett, M.C.; Clarke, D.M. The drug-binding pocket of the human multidrug resistance P-glycoprotein is accessible to the aqueous medium. Biochemistry, 2004, 43, 12081-12089
72. Loo, T.W.; Bartlett, M.C.; Clarke, D.M. Insertion of an arginine residue into the transmembrane segments corrects protein misfolding. J. Biol. Chem., 2006, 281, 29436-29440
73. McDevitt, C.A.; Callaghan, R. How can we best use structural information on P-glycoprotein to design inhibitors? Pharmacol. Ther., 2007, 113, 429-441
74. Lee, B.D.; Li, Z.; French, K.J.; Zhuang, Y.; Xia, Z.; Smith, C.D. Synthesis and evaluation of dihydropyrroloquinolines that selectively antagonize P-glycoprotein. J. Med. Chem., 2004, 47, 1413-1422
75. O'Connor, R. The pharmacology of cancer resistance. Anticancer Res., 2007, 27, 1267-1272
76. Thomas, H.; Coley, H.M. Overcoming multidrug resistance in cancer: an update on the clinical strategy of inhibiting pglycoprotein. Cancer Control, 2003, 10, 159-165
77. Shen, X.L.; Chen, G.Y.; Zhu, G.Y.; Fong, W.F. (+/-)-3′-O,4′- Odicynnamoyl-cis-khellactone, a derivative of (+/-)-praeruptorin A, reverses P-glycoprotein mediated multidrug resistance in cancer cells. Bioorg. Med. Chem., 2006, 14, 7138-7145
78. Kars, M.D.; Iseri, O.D.; Gunduz, U.; Molnar, J. Reversal of multidrug resistance by synthetic and natural compounds in drug-resistant MCF-7 cell lines. Chemotherapy, 2008, 54, 194-200. (Pubitemid 351929270)
79. Ren, Y.; Wang, Y.; Zhang, Y.; Wei, D. Overcoming multidrug resistance in human carcinoma cells by an antisense oligodeoxynucleotide - doxorubicin conjugate in vitro and in vivo. Mol. Pharm., 2008, 5, 579-587
80. Chen, F.; Wang, T.; Wang, J.; Wang, Z.Q.; Qian, M. Levistolide A overcomes P-glycoprotein-mediated drug resistance in human breast carcinoma cells. Acta Pharmacol. Sin., 2008, 29, 458-464 (Pubitemid 351465503)
81. Shen, J.; Zhang, W.; Wu, J.; Zhu, Y. The synergistic reversal effect of multidrug resistance by quercetin and hyperthermia in doxorubicin-resistant human myelogenous leukemia cells. Int. J. Hyperthermia, 2008, 24, 151-159 (Pubitemid 351279955)
82. Venkatesh, K.K.; Biswas, J.; Kumarasamy, N. Impact of highly active antiretroviral therapy on ophthalmic manifestations in human immunodeficiency virus / acquired immune deficiency syndrome. Indian J. Ophthalmol., 2008, 56, 391-393
83. Merenstein, D.; Yang, Y.; Schneider, M.F.; Goparaju, L.; Weber, K.; Sharma, A.; Levine, A.M.; Sharp, G.B.; Gandhi, M.; Liu, C. Association of complementary and alternative medicine use with highly active antiretroviral therapy initiation. Altern. Ther. Health Med., 2008, 14, 18-22.
84. Petriz, J.; Gottesman, M.M.; Aran, J.M. An MDR-EGFP gene fusion allows for direct cellular localization, function and stability assessment of P-glycoprotein. Curr. Drug Deliv., 2004, 1, 43-56.
85. Shaik, N.; Giri, N.; Pan, G.; Elmquist, W.F. P-glycoprotein-mediated active efflux of the anti-HIV1 nucleoside abacavir limits cellular accumulation and brain distribution. Drug Metab. Dispos., 2007, 35, 2076-2085
86. Choo, E.F.; Leake, B.; Wandel, C.; Imamura, H.; Wood, A.J.J.; Wilkinson, G.R.; Kim, R.B. Pharmacological inhibition of Pglycoprotein transport enhances the distribution of HIV-1 protease inhibitors into brain and testes. Drug Metab. Dispos., 2000, 28, 655-660
87. Kageyama, M.; Namiki, H.; Fukushima, H.; Terasaka, S.; Togawa, T.; Tanaka, A.; Ito, Y.; Shibata, N.; Takada, K. Effect of chronic administration of ritonavir on function of cytochrome P450 3A and P-glycoprotein in rats. Biol. Pharm. Bull., 2005, 28, 130-137 (Pubitemid 40879797)
88. Pal, D.; Mitra, A.K. MDR- and CYP3A4-mediated drug-drug interactions. J. Neuroimmune Pharmacol., 2006, 1, 323-339
89. Cianfriglia, M.; Dupuis, M.L.; Molinari, A.; Verdoliva, A.; Costi, R.; Galluzzo, C.M.; Andreotti, M.; Cara, A.; Di Santo, R.; Palmisano, L. HIV-1 integrase inhibitors are substrates for the multidrug transporter MDR1-P-glycoprotein. Retrovirology, 2007, 4, 17.
90. Maffeo, A.; Bellomi, F.; Solimeo, I.; Bambacioni, F.; Scagnolari, C.; De Pisa, F.; Dupuis, M.L.; Cianfriglia, M.; Antonelli, G.; Turriziani, O. P-glycoprotein expression affects the intracellular concentration and antiviral activity of the protease inhibitor saquinavir in a T cell line. New Microbiol., 2004, 27, 119-126 (Pubitemid 40090999)
91. Schwab, A.E.; Churcher, T.S.; Schwab, A.J.; Basáñez, M.G.; Prichard, R.K. An analysis of the population genetics of potential multi-drug resistance in Wuchereria bancrofti due to combination chemotherapy. Parasitology, 2007, 134, 1025-1040 (Pubitemid 46933278)
92. Lüscher, A.; de Koning, H.P.; Mäser, P. Chemotherapeutic strategies against Trypanosoma brucei: drug targets vs. drug targeting. Curr. Pharm. Des., 2007, 13, 555-567 (Pubitemid 46477743)
93. Kerboeuf, D.; Blackhall, W.; Kaminsky, R.; von Samson-Himmelstjerna, G. P-glycoprotein in helminths: function and perspectives for anthelmintic treatment and reversal of resistance. Int. J. Antimicrob. Agents, 2003, 22, 332-346
94. Cortés-Selva, F.; Jiménez, I.A.; Munoz-Martínez, F.; Campillo, M.; Bazzocchi, I.L.; Pardo, L.; Ravelo, A.G.; Castanys, S.; Gamarro, F. Dihydro-beta-agarofuran sesquiterpenes: a new class of reversal agents of the multidrug resistance phenotype mediated by Pglycoprotein in the protozoan parasite Leishmania. Curr. Pharm. Des., 2005, 11, 3125-3139 (Pubitemid 41149929)
95. Collaco, J.M.; Cutting, G.R. Update on gene modifiers in cystic fibrosis. Curr. Opin. Pulm. Med., 2008, 14, 559-566
96. He, L.; Aleksandrov, A.A.; Serohijos, A.W.; Hegedus, T.; Aleksandrov, L.A.; Cui, L.; Dokholyan, N.V.; Riordan, J.R. Multiple membrane-cytoplasmic domain contacts in the cystic fibrosis transmembrane conductance regulator (CFTR) mediate regulation of channel gating. J. Biol. Chem., 2008, 283, 26383-26390
97. Loo, T.W.; Bartlett, M.C.; Clarke, D.M. Rescue of folding defects in ABC transporters using pharmacological chaperones. J. Bioenerg. Biomembr., 2005, 37, 501-507
98. Naumann, N.; Siratska, O.; Gahr, M.; Rosen-Wolff, A. Pglycoprotein expression increases ATP release in respiratory cystic fibrosis cells. J. Cyst. Fibros., 2005, 4, 157-168 (Pubitemid 41200477)
99. Bauer, B. Comment on: 'antidepressant medications and other treatments of depressive disorders: a CINP Task Force report based on a review of evidence'. Int. J. Neuropsychopharmacol., 2008, 11, 577-578 (Pubitemid 351744815)
100. Cirrito, J.R.; Deane, R.; Fagan, A.M.; Spinner, M.L.; Parsadanian, M.; Finn, M.B.; Jiang, H.; Prior, J.L.; Sagare, A.; Bales, K.R.; Paul, S.M.; Zlokovic, B.V.; Piwnica-Worms, D.; Holtzman, D.M. Pglycoprotein deficiency at the blood-brain barrier increases amyloid-beta deposition in an Alzheimer disease mouse model. J. Clin. Invest., 2005, 115, 3285-3290
101. Benderra, Z.; Faussat, A.M.; Sayada, L.; Perrot, J.Y.; Tang, R.P.; Chaoui, D.; Morjani, H.; Marzac, C.; Marie, J.P.; Legrand, O. MRP3, BCRP, and P-glycoprotein activities are prognostic factors in adult acute myeloid leukemia. Clin. Cancer Res., 2005, 11, 7764-7772
102. Ross, D.D. Modulation of drug resistance transporters as a strategy for treating myelodysplastic syndrome. Best Pract. Res. Clin. Haematol., 2004, 17, 641-651
103. Lazarowski, A.J.; Rivello, H.J.G.; Janavel, G.L.V.; Cuniberti, L.A.; Meckert, P.M.C.; Yannarelli, G.G.; Mele, A.; Crottogini, A.J.; Laguens, R.P. Cardiomyocytes of chronically ischemic pig hearts express the MDR-1 gene-encoded P-glycoprotein. J. Histochem. Cytochem., 2005, 53, 845-850
104. Buyse, M.; Radeva, G.; Bado, A.; Farinotti, R. Intestinal inflammation induces adaptation of P-glycoprotein expression and activity. Biochem. Pharmacol., 2005, 69, 1745-1754
105. Brinkmann, U. Functional polymorphisms of the human multidrug resistance (MDR1) gene: correlation with P glycoprotein expression and activity in vivo. Novartis Found Symp., 2002, 243, 207-210
106. Hoffmeyer, S.; Burk, O.; von Richter, O.; Arnold, H.P.; Brockmöller, J.; Johne, A.; Cascorbi, I.; Gerloff, T.; Roots, I.; Eichelbaum, M.; Brinkmann, U. Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. Proc. Natl. Acad. Sci. USA., 2000, 97, 3473-3478
107. Sharom FJ. Shedding light on drug transport: structure and function of the P-glycoprotein multidrug transporter (ABCB1). Biochem. Cell Biol., 2006, 84, 979-992
108. Pauli-Magnus, C.; Kroetz, D.L. Functional implications of genetic polymorphisms in the multidrug resistance gene MDR1 (ABCB1). Pharm. Res., 2004, 21, 904-913
109. Fromm, M.F. The influence of MDR1 polymorphisms on Pglycoprotein expression and function in humans. Adv. Drug Deliv. Rev., 2002, 54, 1295-1310.
110. Rosso Felipe, C.; de Sandes, T.V.; Sampaio, E.L.; Park, S.I.; Silva, H.T. Jr.; Medina Pestana, J.O. Clinical impact of polymorphisms of transport proteins and enzymes involved in the metabolism of immunosuppressive drugs. Transplant Proc., 2009, 41, 1441-1455
111. Ekhart, C.; Rodenhuis, S.; Smits, P.H.; Beijnen, J.H.; Huitema, A.D. An overview of the relations between polymorphisms in drug metabolising enzymes and drug transporters and survival after cancer drug treatment. Cancer Treat. Rev., 2009, 35, 18-31.
112. Maeda, K.; Sugiyama, Y. Impact of genetic polymorphisms of transporters on the pharmacokinetic, pharmacodynamic and toxicological properties of anionic drugs. Drug Metab. Pharmacokinet., 2008, 23, 223-235
113. Fung, K.L.; Gottesman, M.M. A synonymous polymorphism in a common MDR1 (ABCB1) haplotype shapes protein function. Biochim. Biophys. Acta, 2009, 1794, 860-871
114. Kim, H.J.; Hwang, S.Y.; Kim, J.H,.; Park, H.J.; Lee, S.G.; Lee, S.W.; Joo, J.C.; Kim, Y.K. Association between Genetic Polymorphism of Multidrug Resistance 1 Gene and Sasang Constitutions. Evid. Based Complement Alternat. Med., 2009, Suppl 1, 73-80.
115. Goto, M.; Masuda, S.; Saito, H.; Uemoto, S.; Kiuchi, T.; Tanaka, K. C3435T polymorphism in the MDR1 gene affects the enterocyte expression level of CYP3A4 rather than Pgp in recipients living donor liver transplantation. Pharmacogenetics, 2002, 12, 451-457
116. Schaich, M,.; Kestel, L.; Pfirrmann, M.; Robel, K.; Illmer, T.; Kramer, M,.; Dill, C.; Ehninger, G.; Schackert, G.; Krex, D. A MDR1 (ABCB1) gene single nucleotide polymorphism predicts outcome of temozolomide treatment in glioblastoma patients. Ann. Oncol., 2009, 20, 175-181
117. Jamroziak, K.; Robak, T. Do polymorphisms in ABC transporter genes influence risk of childhood acute lymphoblastic leukemia? Leuk. Res., 2008, 32, 1173-1175
118. Walters, T.D.; Silverberg, M.S. Genetics of inflammatory bowel disease: current status and future directions. Can. J. Gastroenterol., 2006, 20, 633-639
119. Annese, V.; Valvano, M.R.; Palmieri, O.; Latiano, A.; Bossa, F.; Andriulli, A. Multidrug resistance 1 gene in inflammatory bowel disease: a meta-analysis. World J. Gastroenterol., 2006, 12, 3636-3644 (Pubitemid 43950939)
120. Poduri, A.; Khullar, M.; Bahl, A.; Sharma, Y.P.; Talwar, K.K. A combination of proatherogenic single-nucleotide polymorphisms is associated with increased risk of coronary artery disease and myocardial infarction in Asian Indians. DNA Cell Biol., 2009, 28, 451-460
121. Löscher, W.; Delanty, N. MDR1/ABCB1 polymorphisms and multidrug resistance in epilepsy: in and out of fashion. Pharmacogenomics, 2009, 10, 711-713
122. Westerlund M, Belin AC, Anvret A, Håkansson A, Nissbrandt H, Lind C, Sydow O, Olson L, Galter D. Association of a polymorphism in the ABCB1 gene with Parkinson's disease. Parkinsonism Relat. Disord., 2009, 15, 422-424
123. Sauna, Z.E.; Kimchi-Sarfaty, C.; Ambudkar, S.V.; Gottesman, M.M. Silent polymorphisms speak: how they affect pharmacogenomics and the treatment of cancer. Cancer Res., 2007, 67, 9609-9612
124. Jamroziak, K.; Balcerczak, E.; Calka, K.; Piaskowski, S.; Urbanska-Rys, H.; Salagacka, A.; Mirowski, M.; Robak, T. Polymorphisms and haplotypes in the multidrug resistance 1 gene (MDR1/ABCB1) and risk of multiple myeloma. Leuk. Res., 2009, 33, 332-335
125. Ekhart, C.; Rodenhuis, S.; Smits, P.H.; Beijnen, J.H.; Huitema, A.D. An overview of the relations between polymorphisms in drug metabolising enzymes and drug transporters and survival after cancer drug treatment. Cancer Treat. Rev., 2009, 35, 18-31.
126. Bosch, T.M. Pharmacogenomics of drug-metabolizing enzymes and drug transporters in chemotherapy. Methods Mol. Biol., 2008, 448, 63-76.
127. Thews, O.; Gassner, B.; Kelleher, D.K.; Schwerdt, G.; Gekle, M. Impact of extracellular acidity on the activity of P-glycoprotein and the cytotoxicity of chemotherapeutic drugs. Neoplasia, 2006, 8, 143-152